Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 449

1.

Serum tumor antigen REG4 as a diagnostic biomarker in pancreatic ductal adenocarcinoma.

Takayama R, Nakagawa H, Sawaki A, Mizuno N, Kawai H, Tajika M, Yatabe Y, Matsuo K, Uehara R, Ono K, Nakamura Y, Yamao K.

J Gastroenterol. 2010;45(1):52-9. doi: 10.1007/s00535-009-0114-y. Epub 2009 Sep 30.

PMID:
19789838
2.

Serum macrophage inhibitory cytokine 1 as a marker of pancreatic and other periampullary cancers.

Koopmann J, Buckhaults P, Brown DA, Zahurak ML, Sato N, Fukushima N, Sokoll LJ, Chan DW, Yeo CJ, Hruban RH, Breit SN, Kinzler KW, Vogelstein B, Goggins M.

Clin Cancer Res. 2004 Apr 1;10(7):2386-92.

3.

Serum markers in patients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA19-9.

Koopmann J, Rosenzweig CN, Zhang Z, Canto MI, Brown DA, Hunter M, Yeo C, Chan DW, Breit SN, Goggins M.

Clin Cancer Res. 2006 Jan 15;12(2):442-6.

4.

CEACAM1, a novel serum biomarker for pancreatic cancer.

Simeone DM, Ji B, Banerjee M, Arumugam T, Li D, Anderson MA, Bamberger AM, Greenson J, Brand RE, Ramachandran V, Logsdon CD.

Pancreas. 2007 May;34(4):436-43.

PMID:
17446843
5.

Novel tumor marker REG4 detected in serum of patients with resectable pancreatic cancer and feasibility for antibody therapy targeting REG4.

Takehara A, Eguchi H, Ohigashi H, Ishikawa O, Kasugai T, Hosokawa M, Katagiri T, Nakamura Y, Nakagawa H.

Cancer Sci. 2006 Nov;97(11):1191-7. Epub 2006 Aug 17.

6.

Expression and diagnostic evaluation of the human tumor-associated antigen RCAS1 in pancreatic cancer.

Akashi T, Oimomi H, Nishiyama K, Nakashima M, Arita Y, Sumii T, Kimura T, Ito T, Nawata H, Watanabe T.

Pancreas. 2003 Jan;26(1):49-55.

PMID:
12499917
7.

Serum tumor antigen REG4 as a useful diagnostic biomarker in gastric cancer.

Kobayashi Y, Niwa Y, Tajika M, Kawai H, Kondo S, Hara K, Mizuno N, Hijioka S, Sawaki A, Matsuo K, Nakagawa H, Nakamura Y, Yamao K.

Hepatogastroenterology. 2010 Nov-Dec;57(104):1631-4.

PMID:
21443133
8.

[Evaluation of RCAS1 as serum tumor marker for pancreatic cancer].

Yang YC, Zhao YP, Liao Q, Zhang TP, Hu Y, Dai MH.

Zhonghua Wai Ke Za Zhi. 2009 Jul 1;47(13):999-1001. Chinese.

PMID:
19957811
9.

Serum heat shock protein 27 is increased in chronic pancreatitis and pancreatic carcinoma.

Liao WC, Wu MS, Wang HP, Tien YW, Lin JT.

Pancreas. 2009 May;38(4):422-6. doi: 10.1097/MPA.0b013e318198281d.

PMID:
19214136
10.

Evaluation of the diagnostic value of serum tumor markers, and fecal k-ras and p53 gene mutations for pancreatic cancer.

Wu X, Lu XH, Xu T, Qian JM, Zhao P, Guo XZ, Yang XO, Jiang WJ.

Chin J Dig Dis. 2006;7(3):170-4.

PMID:
16808798
11.

Comparison of plasma Tu-M2-PK and CA19-9 in pancreatic cancer.

Joergensen MT, Heegaard NH, Schaffalitzky de Muckadell OB.

Pancreas. 2010 Mar;39(2):243-7. doi: 10.1097/MPA.0b013e3181bae8ab.

PMID:
19820423
12.

A new strategy for the application of CA19-9 in the differentiation of pancreaticobiliary cancer: analysis using a receiver operating characteristic curve.

Kim HJ, Kim MH, Myung SJ, Lim BC, Park ET, Yoo KS, Seo DW, Lee SK, Min YI.

Am J Gastroenterol. 1999 Jul;94(7):1941-6.

PMID:
10406263
13.

Improved diagnosis of pancreatic adenocarcinoma using haptoglobin and serum amyloid A in a panel screen.

Firpo MA, Gay DZ, Granger SR, Scaife CL, DiSario JA, Boucher KM, Mulvihill SJ.

World J Surg. 2009 Apr;33(4):716-22. doi: 10.1007/s00268-008-9853-9.

14.

Combined detection of serum tumor markers for differential diagnosis of solid lesions located at the pancreatic head.

Liao Q, Zhao YP, Yang YC, Li LJ, Long X, Han SM.

Hepatobiliary Pancreat Dis Int. 2007 Dec;6(6):641-5.

15.

Clinical significance of cathepsin E in pancreatic juice in the diagnosis of pancreatic ductal adenocarcinoma.

Uno K, Azuma T, Nakajima M, Yasuda K, Hayakumo T, Mukai H, Sakai T, Kawai K.

J Gastroenterol Hepatol. 2000 Nov;15(11):1333-8.

PMID:
11129230
16.

Serum high mobility group box-1 is a powerful diagnostic and prognostic biomarker for pancreatic ductal adenocarcinoma.

Chung HW, Lim JB, Jang S, Lee KJ, Park KH, Song SY.

Cancer Sci. 2012 Sep;103(9):1714-21. doi: 10.1111/j.1349-7006.2012.02358.x. Epub 2012 Jul 30.

17.

Early diagnosis of pancreatic cancer: neutrophil gelatinase-associated lipocalin as a marker of pancreatic intraepithelial neoplasia.

Moniaux N, Chakraborty S, Yalniz M, Gonzalez J, Shostrom VK, Standop J, Lele SM, Ouellette M, Pour PM, Sasson AR, Brand RE, Hollingsworth MA, Jain M, Batra SK.

Br J Cancer. 2008 May 6;98(9):1540-7. doi: 10.1038/sj.bjc.6604329. Epub 2008 Apr 8.

18.

Serum diagnosis of pancreatic adenocarcinoma using surface-enhanced laser desorption and ionization mass spectrometry.

Koopmann J, Zhang Z, White N, Rosenzweig J, Fedarko N, Jagannath S, Canto MI, Yeo CJ, Chan DW, Goggins M.

Clin Cancer Res. 2004 Feb 1;10(3):860-8.

19.

Identification of Cystatin SN as a novel tumor marker for colorectal cancer.

Yoneda K, Iida H, Endo H, Hosono K, Akiyama T, Takahashi H, Inamori M, Abe Y, Yoneda M, Fujita K, Kato S, Nozaki Y, Ichikawa Y, Uozaki H, Fukayama M, Shimamura T, Kodama T, Aburatani H, Miyazawa C, Ishii K, Hosomi N, Sagara M, Takahashi M, Ike H, Saito H, Kusakabe A, Nakajima A.

Int J Oncol. 2009 Jul;35(1):33-40.

PMID:
19513549
20.

Evaluation of osteopontin as biomarker for pancreatic adenocarcinoma.

Koopmann J, Fedarko NS, Jain A, Maitra A, Iacobuzio-Donahue C, Rahman A, Hruban RH, Yeo CJ, Goggins M.

Cancer Epidemiol Biomarkers Prev. 2004 Mar;13(3):487-91.

Items per page

Supplemental Content

Write to the Help Desk